In this podcast, first recorded at the 2021 IO360° Summit, Dr Peter Marks, Center for Biologics Evaluation and Research (CBER), FDA, moderated a panel on the evolution of regulatory policy for cell/gene therapy.
Discussion points include:
Jeff Allen, PhD, Friends of Cancer Research
Anne Chew, PhD, University of Pennsylvania
Alberto Santagostino, Lonza Pharma & Biotech
To learn more about the upcoming 2021 IO360° conference, please visit www.io360summit.com